Details

Autor(en) / Beteiligte

• Matsunaga, Shigeo
• Shuto, Takashi
• Yamamoto, Masaaki
• Yomo, Shoji
• Kondoh, Takeshi
• Kobayashi, Tatsuya
• Sato, Manabu
• Okamoto, Hisayo
• Serizawa, Toru
• Nagano, Osamu
• Kenai, Hiroyuki
• Obara, Takuma
• Iwai, Yoshiyasu
• Yasuda, Soichiro
• Hasegawa, Toshinori
• Kubo, Kenji
• Shidoh, Satoka
• Mori, Katsuharu
• Hayashi, Motohiro
• Inoue, Akira
• Onoue, Shinji
• Gondo, Masazumi

Titel

Gamma Knife Radiosurgery for Metastatic Brain Tumors from Malignant Melanomas: A Japanese Multi-Institutional Cooperative and Retrospective Cohort Study (JLGK1501)

Ist Teil von

• Stereotactic and functional neurosurgery, 2018-01, Vol.96 (3), p.162

Ort / Verlag

Switzerland

Erscheinungsjahr

2018

Link zum Volltext

Beschreibungen/Notizen

• The incidences of metastatic brain tumors from malignant melanomas have increased and survival has been prolonged by novel molecular targeted agents and immunotherapy. However, malignant melanomas are uncommon in Asian populations. We retrospectively analyzed treatment efficacy and identified prognostic factors impacting tumor control and survival in Japanese melanoma patients with brain metastases treated with gamma knife radiosurgery (GKRS). We retrospectively reviewed the medical records of 177 patients with 1,500 tumors who underwent GKRS for brain metastases from malignant melanomas. This study was conducted by the Japanese Leksell Gamma Knife Society (JLGK1501). Six and 12 months after GKRS, the cumulative incidences of local tumor recurrence were 9.2 and 13.8%. Intratumoral hemorrhage (p < 0.0001) and larger tumor volume (p = 0.001) in GKRS were associated with significantly poorer local control outcomes. The use of immune checkpoint inhibitors before GKRS was significantly associated with symptomatic adverse events (p = 0.037). The median overall survival time after the initial GKRS was 7.3 months. Lower Karnofsky performance status scores (p = 0.016), uncontrolled primary cancer (p < 0.0001), and multiple brain metastases (p = 0.014) significantly influenced unfavorable overall survival outcomes. The cumulative incidences of neurological death 6 and 12 months after GKRS were 9.7 and 17.4%, those of neurological deterioration were 14.2 and 19.6%, and those of new tumor appearance were 34.5 and 40.5%. The results of the present multicenter study suggest that GKRS is a relatively effective and safe modality for control of tumor progression in Japanese patients with brain metastases from malignant melanomas.